BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People’s Republic of China and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$385.24|
|52 Week High||US$219.20|
|52 Week Low||US$388.97|
|1 Month Change||36.84%|
|3 Month Change||19.71%|
|1 Year Change||46.69%|
|3 Year Change||136.49%|
|5 Year Change||1,135.54%|
|Change since IPO||1,260.31%|
Recent News & Updates
|BGNE||US Biotechs||US Market|
Return vs Industry: BGNE exceeded the US Biotechs industry which returned 24.9% over the past year.
Return vs Market: BGNE exceeded the US Market which returned 33.7% over the past year.
Stable Share Price: BGNE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: BGNE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People’s Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors.
BeiGene Fundamentals Summary
|BGNE fundamental statistics|
Is BGNE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BGNE income statement (TTM)|
|Cost of Revenue||US$1.41b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-14.49|
|Net Profit Margin||-138.52%|
How did BGNE perform over the long term?See historical performance and comparison
Is BeiGene undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BGNE ($385.24) is trading below our estimate of fair value ($712.78)
Significantly Below Fair Value: BGNE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BGNE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BGNE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BGNE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BGNE is overvalued based on its PB Ratio (9.9x) compared to the US Biotechs industry average (3.2x).
How is BeiGene forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BGNE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BGNE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BGNE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BGNE's revenue (25.8% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: BGNE's revenue (25.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BGNE is forecast to be unprofitable in 3 years.
How has BeiGene performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BGNE is currently unprofitable.
Growing Profit Margin: BGNE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BGNE is unprofitable, and losses have increased over the past 5 years at a rate of 50% per year.
Accelerating Growth: Unable to compare BGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: BGNE has a negative Return on Equity (-36.41%), as it is currently unprofitable.
How is BeiGene's financial position?
Financial Position Analysis
Short Term Liabilities: BGNE's short term assets ($4.5B) exceed its short term liabilities ($706.6M).
Long Term Liabilities: BGNE's short term assets ($4.5B) exceed its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: BGNE's debt to equity ratio (17.5%) is considered satisfactory.
Reducing Debt: BGNE's debt to equity ratio has increased from 4.8% to 17.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGNE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BGNE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is BeiGene current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BGNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BGNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BGNE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BGNE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BGNE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Oyler (53 yo)
Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD14.41M) is about average for companies of similar size in the US market ($USD11.33M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: BGNE's management team is considered experienced (3.3 years average tenure).
Experienced Board: BGNE's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BGNE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.
BeiGene, Ltd.'s employee growth, exchange listings and data sources
- Name: BeiGene, Ltd.
- Ticker: BGNE
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$35.842b
- Shares outstanding: 93.04m
- Website: https://www.beigene.com
Number of Employees
- BeiGene, Ltd.
- 94 Solaris Avenue
- Camana Bay
- Grand Cayman
- Grand Cayman
- Cayman Islands
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 22:55|
|End of Day Share Price||2021/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.